The CARES Act funding was a lifeline for many health care organizations and life sciences companies, but came with significant attached strings. Related fraud charges are already making headlines and bring with them the serious risk of False Claims Act litigation, which can have bet-the-company implications for companies. Please join us this Wednesday, August 5 at 2 p.m. ET for a CLE webinar on “Preparing for the inevitable: FCA investigations in a post-COVID world…

While the life sciences sector has proven more resilient than most, COVID-19 has undoubtedly caused a dramatic slowdown in deal activity globally across industries. Please join Reed Smith and a panel of strategic, private equity, and venture capital leading deal makers for an engaging discussion on the impact COVID-19 has had on deal making in the life sciences sector, lessons learned, and their perspectives on deal making and deal trends in the sector in a…

The German Federal Ministry for Economic Affairs and Energy implemented further amendments to the Foreign Trade and Payments Ordinance (Außenwirtschaftsverordnung – AWV) due to the COVID-19 pandemic to prevent the buyout of German companies active in the life sciences and infection protection sectors by investors from outside the EU (or EFTA). The amendment entered into force on 3 June 2020. The amendment broadens the scope of application of cross-sector reviews. In particular, the development and…

On 2 June, the European Commission (Commission) published a roadmap (Roadmap) that will pave the way for the Commission’s communication on the EU pharmaceutical strategy, which is now due in the last quarter of 2020. The Roadmap should be read together with the Commission’s proposal for a recovery of the EU’s economy (Next Generation EU), which was published on 27 May and which includes a section on lessons learned from the…

Reed Smith partner Kevin Madagan and associate Julia Lake will return for a second year to help lead a four-hour “Ad Promo Primer” at the Drug Information Association (DIA)’s “Advertising and Promotion Regulatory Affairs Conference,” which will be held virtually May 18-20, 2020. In addition, Kevin, a member of this year’s planning committee, will be leading a DIA discussion about pricing disclosures and communications.…

California Governor Gavin Newsom’s Executive Order N-43-20 (the Order), which went into effect on April 3, 2020, relaxes various telehealth reporting requirements, penalties, and enforcements otherwise imposed under state laws, including those associated with unauthorized access and disclosure of personal information through telehealth mediums.  The Order acknowledged that telehealth services may help reduce the spread of COVID-19, and strict compliance with certain state telehealth requirements would otherwise “prevent, hinder, or delay appropriate actions to prevent…

Pharmaceutical manufacturers, as well as other companies affected by or included in changes to pharmaceutical supply chains, are invited to join us tomorrow, April 7, for a complimentary webinar focused on current issues facing the global pharmaceutical supply chain. Reed Smith partners J.P. Duffy, Iqbal Hussain, and John Ellison will offer an engaging discussion on: The steps that companies need to take now given the potential for international arbitration claims to arise from…